Dose fractionation in 131I-metaiodobenzylguanidine (MIBG) therapy: should the tumour biology and intent of therapy be the guide?

被引：0
作者：
Sandip Basu
机构：
[1] Tata Memorial Hospital Annexe,Radiation Medicine Centre (B.A.R.C)
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2010年 / 37卷
关键词：
Paraganglioma; Phaeochromocytoma; Malignant Phaeochromocytoma; Metastatic Neuroendocrine Tumour; Neural Crest Tumour;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1798 / 1799
页数：1
相关论文
共 22 条
  • [21] [177Lu]Lu-DOTA-TATE and [131I]MIBG Phenotypic Imaging-Based Therapy in Metastatic/Inoperable Pheochromocytomas and Paragangliomas: Comparative Results in a Single Center
    Prado-Wohlwend, Stefan
    del Olmo-Garcia, Maria Isabel
    Bello-Arques, Pilar
    Merino-Torres, Juan Francisco
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [22] Response to targeted radionuclide therapy with [131I]MIBG AND [177Lu]Lu-DOTA-TATE according to adrenal vs. extra-adrenal primary location in metastatic paragangliomas and pheochromocytomas: A systematic review
    Prado-Wohlwend, Stefan
    Isabel del Olmo-Garcia, Maria
    Bello-Arques, Pilar
    Francisco Merino-Torres, Juan
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
123